Company

Epigenomics AG

Headquarters: Berlin, Germany

Employees: 32

CEO: Mr. Gregory Hamilton

Market Cap

€6.2 Million

EUR as of Jan. 1, 2023

US$6.6 Million

history Market Cap History

Epigenomics AG market capitalization over time

Evolution of Epigenomics AG market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Epigenomics AG

Detailed Description

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Stocks & Indices

Epigenomics AG has the following listings and related stock indices.


Stock: FSX: ECX

Stock: XETR: ECX

Stock: OTC: EPGNY

Stock: OTC: EPGNF

Details

Headquarters:

Geneststrasse 5

Berlin, 10829

Germany

Phone: 49 30 243 450

Fax: 49 30 2434 5555